Skip to main content
. 2011 Nov 22;17(10):960–987. doi: 10.1038/mp.2011.138

Figure 1.

Figure 1

Plotted is the sample size (cases+controls) analyzed in the first meta-analyses of the Psychiatric Genome-Wide Association Study (GWAS) Consortium on schizophrenia, bipolar disorder, major depressive disorder, autistic spectrum disorders and attention deficit/hyperactivity disorder (ADHD) against the −log of the minimal association P-value observed in the GWAS. The P-value indicating genome-wide significance of findings is indicated. The data show the strong (r=0.91) and significant (P=0.03) correlation between the two parameters. Drawing a line through the points suggests that at least 12 000 samples (cases+controls) will be needed before genome-wide significant findings for ADHD will be observed.